Case Review Form

      * Denotes required field.


      * First Name

      * Last Name

      * Email Address

      * Phone Number

      Cell Phone Number

      Office Phone Number

      Street Address




      Zip Code

      Please provide the best method and times to contact you:

      Date of birth of injured person

      Name of drug:

      Date you started taking the drug (mm-yyyy):

      Date you stopped taking the drug (mm-yyyy):

      Please describe any side effects:

      Other Info:

      No Yes, I agree to the Parker & Waichman LLP disclaimers.Click here to review all.

      Yes, I would like to receive the Parker & Waichman LLP monthly newsletter, InjuryAlert.

      please do not fill out the field below.

Pradaxa Bleeding Lawsuits Moving Forward

Filed August 3rd, 2012 Laurie

U.S. District Judge David Herndon is continuing to move forward with Pradaxa claims filed in his court.

Last month, Herndon denied a motion made by Defendant Boehringer Ingelheim Pharmaceuticals, which manufactures the blood thinning drug, to stay proceedings until the U.S. Panel for Multi District Litigation (PMDL) ruled on the multidistrict litigation (MDL) request.

Herndon has issued orders on motions seeking extensions of time to file responses and motions to dismiss for failure to state a claim in about a handful of the eight cases filed in May in East St. Louis. In a June order, Herdon wrote that 27 Pradaxa actions were pending in 13 different district courts across the country, with the majority coming from his court. He said “this is far too many cases to ignore the issues that are of concern to this Court while the MDL motion is being resolved.”

Plaintiffs in the cases are suing for negligence, liability for design defects and failure to warn the public about the drug’s risks, fraudulent concealment and negligent misrepresentation, as well as violations of the Illinois Consumer Fraud and Deceptive Practices Act.

Pradaxa has been found to cause serious side effects, including internal bleeding and death.

Boehringer has sought to dismiss, arguing that Pradaxa has always carried a warning about the risk of “serious and sometimes fatal bleeding.”

Be Sociable, Share!

Comments are closed.

Click Here Now, to Have an Attorney Answer Your
Medicinal Drug Injuries Questions
No Cost - No Obligation!